Skip to main content
. 2012 Sep 20;7(9):e45399. doi: 10.1371/journal.pone.0045399

Figure 3. Mφ-c-Myc-KO mice are resistant to growth of tumors derived from injected B16 melanoma cells.

Figure 3

(A) B16 melanoma cells expressing firefly luciferase were injected subcutaneously into both flanks of mice, and tumor growth was monitored over two weeks post-grafting with the Xenogen IVIS 100 Bioluminescence in vivo imaging system (n = 6–8 tumors per genotype). (B) Tumor volume after sacrifice at two weeks post-injection (n = 16 tumors per genotype). (C) Flow cytometry analysis for circulating CD11b+ myeloid cells, CD4+ T lymphocytes, CD8+ T lymphocytes and CD19+ B lymphocytes in mice two weeks after tumor injection (n = 7, control; n = 8 Mφ-c-Myc-KO). (D) Flow cytometry detection of circulating myeloid cells two weeks after tumor injection (n = 7, control; n = 8, Mφ-c-MYC-KO) (E) Representative confocal images showing double immunofluorescence to visualize macrophages (CD68+ cells) and c-MYC expression in tumors, and quantification of c-Myc mRNA in TAMs isolated by sorting tumor cell suspensions (n = 3 mice per genotype; two tumors pooled per mouse). (F) Representative confocal images and quantification of proliferating TAMs (CD68+Ki67+) (n = 6 tumors per genotype). (G) Representative confocal images and quantification of apoptotic TAMs (CD68+TUNEL+) (n = 6 tumors per genotype).